We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Connect Biopharma Holdings Inc | NASDAQ:CNTB | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.72% | 1.38 | 1.37 | 1.47 | 1.49 | 1.33 | 1.45 | 75,338 | 22:09:19 |
A live webcast of this fireside chat will be available on the Company’s Investor Relations page accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.
About Connect Biopharma Holdings LimitedConnect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.
Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) and is currently being evaluated in clinical trials for the treatment of atopic dermatitis (AD) and asthma and in development for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) that is in development for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we are developing CBP-174, a peripherally restricted antagonist of histamine receptor 3, for the treatment of pruritus associated with skin inflammation.
With headquarters in China, additional operations in the United States and Australia, and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.
IR/PR CONTACTS: Lazar FINN Partners David Carey (IR) T: +1-(212) 867-1768david.carey@finnpartners.com
Erich Sandoval (Media) +1-(646) 871-8482 or +1-(917) 497-2867erich.sandoval@finnpartners.com
Corporate Contacts:info@connectpharm.com
1 Year Connect Biopharma Chart |
1 Month Connect Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions